type 2 diabetes
Conditions
Interventions
Continue GLP-1 receptor agonists (regular dose) or switch to tirzepatide.
Participants in the tirzepatide group follow an escalation regimen of 5mg tirzepatide once weekly (maintenance dose reached a
Sponsors
Ohara Makoto
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a diagnosis of type 2 diabetes mellitus 1) HbA1c 7.0% or more 2) Patients who were treated with regular doses of weekly GLP-1 receptor agonists at least for 12 weeks 3) BMI >= 23 4) written informed consent 5) 18 years and over
Exclusion criteria
Exclusion criteria: 1)the use of steroids or anti-inflammatory drugs, 2)diabetic ketosis and coma within 3 months before the study, 3)severe infection, severe trauma, pre-and post-operation, 4)an estimated glomerular filtration rate are within 30mL/min/1.73m2, 5)malignancy, 6)pregnancy 7)Patients who are judged as inappropriate for inclusion by phsicians 8)Patients using implantable medical devices such as cardiac pacemakers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end point was d-ROMs change from baseline after completing 24 weeks of treatment intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) The change in glucose variability at 24 weeks from baseline 2) Glucose metabolism index, lipid metabolism index, Renal function, liver function 3) Eating Behavior Questionnaire and DTSQ 4) Blood pressure, pulse, weight | — |
Contacts
Public ContactMakoto Ohara
Showa Medical University Hospital
Outcome results
None listed